Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Biochim Biophys Acta Mol Basis Dis. 2021 Apr 30;1867(8):166162. doi: 10.1016/j.bbadis.2021.166162

Table 1.

Some of the clinical trial studies of tau-targeting small molecules and their trial status in Alzheimer disease.

Drugs Clinical trial identifier Dates Trial description Trial status

PP2A activators
Memantine NCT03168997 2017–2018 Phase IV open-label, parallel-group interventional study (n = 222) Not yet recruiting
Sodium selenate ACTRN12613000170729 2012–2013 Open-label extension study (n = 20) Completed
GSK3β inhibitors
Tideglusib 2010-023322-21 2013–2015 Phase II randomized, double-blind, placebo-controlled, four- arm efficacy study in mild to moderate AD (n = 306) Completed
Lithium chloride NCT02862210 2016–2020 Phase II randomized, double-blind, placebo-controlled low dose efficacy study in FTDP (n = 60) Not yet recruiting
Aggregation inhibitors
LMTX NCT02245568 2014–2018 Phase III open-label extension study for patients in previous trials (n = 1,000) Terminated
Curcumin NCT00595582 2005–2008 Single-group, open-label, dietary supplement in MCI (n = 10) Terminated
Microtubule stabilizers
Epithilone D NCT01492374 2012–2013 Phase I randomized, double-blind, placebo-controlled trial in mild AD (n = 40) Completed
TPI 287 NCT02133846 2014–2017 Phase I randomized, double-blind, placebo-controlled, sequential-cohort dose-ranging study in CBD and PSP (n = 44) Active, not recruiting